Dendreon Corp. (NASDAQ: DNDN) received FDA approval for a revolutionary prostate cancer drug Thursday that will offer a less intensive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE